MX382056B - P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación. - Google Patents
P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación.Info
- Publication number
- MX382056B MX382056B MX2017011392A MX2017011392A MX382056B MX 382056 B MX382056 B MX 382056B MX 2017011392 A MX2017011392 A MX 2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A MX 382056 B MX382056 B MX 382056B
- Authority
- MX
- Mexico
- Prior art keywords
- crystal form
- toluenesulfonate
- preparation
- kinase inhibitor
- mek kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe un p-toluensulfonato para un inhibidor de MEK cinasa, y una forma de cristal del mismo y un método de preparación del mismo. De manera específica, se describe p-toluensulfonato de 2-((2-fluorine-4-yodofenil)amino)-1-metil-4-((6-metilpiridin-3-grupo)oxigrupo)-6-carbonil-1,6-dihidropiridin-3-formamida (un compuesto representado por la fórmula (I)), y una forma de cristal I y un método de preparación del mismo. La forma de cristal I obtenida del compuesto representada por la fórmula (I) tiene buena estabilidad de forma de cristal y estabilidad química, y un solvente de cristalización usado tiene baja toxicidad y bajo residuo y puede usarse mejor en el tratamiento clínico. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510141303 | 2015-03-27 | ||
| PCT/CN2016/075853 WO2016155473A1 (zh) | 2015-03-27 | 2016-03-08 | 一种mek激酶抑制剂的对甲苯磺酸盐、其结晶形式及制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017011392A MX2017011392A (es) | 2018-01-15 |
| MX382056B true MX382056B (es) | 2025-03-13 |
Family
ID=57005438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011392A MX382056B (es) | 2015-03-27 | 2016-03-08 | P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10118911B2 (es) |
| EP (1) | EP3275866B1 (es) |
| JP (1) | JP2018509407A (es) |
| KR (1) | KR20170131506A (es) |
| CN (1) | CN106795116B (es) |
| AU (1) | AU2016239028B2 (es) |
| BR (1) | BR112017018580A2 (es) |
| CA (1) | CA2978796A1 (es) |
| MX (1) | MX382056B (es) |
| RU (1) | RU2704251C2 (es) |
| TW (1) | TWI705060B (es) |
| WO (1) | WO2016155473A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041561A1 (en) | 2016-11-25 | 2018-05-31 | Jiangsu Hengrui Medicine Co., Ltd. | Pyridone derivative pharmaceutical composition and preparation method thereof |
| TW201821408A (zh) * | 2016-12-01 | 2018-06-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種吡啶酮類衍生物的製備方法及其中間體 |
| WO2020156162A1 (zh) * | 2019-01-29 | 2020-08-06 | 贝达药业股份有限公司 | Mek抑制剂及其在医药上的应用 |
| TW202114994A (zh) * | 2019-07-29 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種1,6-二氫吡啶-3-甲醯胺衍生物的製備方法 |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス, インコーポレイテッド | 併用療法 |
| CN118973580A (zh) | 2022-04-08 | 2024-11-15 | 米拉蒂治疗股份有限公司 | 包含sos1抑制剂和mek抑制剂的组合疗法 |
| CN119768393A (zh) * | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| CN120441478A (zh) * | 2024-02-07 | 2025-08-08 | 成都赜灵生物医药科技有限公司 | 一种六元内酰胺类化合物及其应用 |
| WO2026085809A1 (zh) * | 2024-10-24 | 2026-04-30 | 上海复星医药产业发展有限公司 | 蛋白激酶抑制剂的药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1272290B (it) * | 1994-06-20 | 1997-06-16 | Avantgarde Spa | Sale della l-carnitina e composizioni farmaceutiche che lo contengono per il trattamento di affezioni cutanee |
| US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| EP2279166A1 (en) * | 2008-04-22 | 2011-02-02 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenoxybenzamides |
| EP2382216A1 (en) * | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| CN102459188A (zh) * | 2009-06-15 | 2012-05-16 | 凯美隆(北京)药业技术有限公司 | 新型6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| US20120238599A1 (en) * | 2011-03-17 | 2012-09-20 | Chemizon, A Division Of Optomagic Co., Ltd. | Heterocyclic compounds as mek inhibitors |
| WO2014204263A1 (en) * | 2013-06-20 | 2014-12-24 | The Asan Foundation | Substituted pyridinone compounds as mek inhibitors |
| EP3061747B1 (en) * | 2013-10-25 | 2021-04-07 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
-
2016
- 2016-03-08 BR BR112017018580-6A patent/BR112017018580A2/pt active Search and Examination
- 2016-03-08 MX MX2017011392A patent/MX382056B/es unknown
- 2016-03-08 CN CN201680001860.4A patent/CN106795116B/zh active Active
- 2016-03-08 CA CA2978796A patent/CA2978796A1/en not_active Abandoned
- 2016-03-08 JP JP2017545735A patent/JP2018509407A/ja active Pending
- 2016-03-08 EP EP16771228.0A patent/EP3275866B1/en active Active
- 2016-03-08 KR KR1020177029896A patent/KR20170131506A/ko not_active Ceased
- 2016-03-08 WO PCT/CN2016/075853 patent/WO2016155473A1/zh not_active Ceased
- 2016-03-08 AU AU2016239028A patent/AU2016239028B2/en not_active Ceased
- 2016-03-08 RU RU2017134709A patent/RU2704251C2/ru active
- 2016-03-08 US US15/559,516 patent/US10118911B2/en not_active Expired - Fee Related
- 2016-03-22 TW TW105108789A patent/TWI705060B/zh not_active IP Right Cessation
-
2018
- 2018-09-10 US US16/125,896 patent/US20180370948A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI705060B (zh) | 2020-09-21 |
| CN106795116A (zh) | 2017-05-31 |
| US10118911B2 (en) | 2018-11-06 |
| WO2016155473A1 (zh) | 2016-10-06 |
| RU2017134709A3 (es) | 2019-07-17 |
| CN106795116B (zh) | 2019-11-01 |
| CA2978796A1 (en) | 2016-10-06 |
| EP3275866A4 (en) | 2018-08-15 |
| RU2704251C2 (ru) | 2019-10-25 |
| AU2016239028A1 (en) | 2017-09-14 |
| US20180370948A1 (en) | 2018-12-27 |
| BR112017018580A2 (pt) | 2018-04-24 |
| RU2017134709A (ru) | 2019-04-29 |
| TW201634459A (zh) | 2016-10-01 |
| US20180118715A1 (en) | 2018-05-03 |
| AU2016239028B2 (en) | 2019-09-19 |
| EP3275866B1 (en) | 2019-12-04 |
| MX2017011392A (es) | 2018-01-15 |
| JP2018509407A (ja) | 2018-04-05 |
| EP3275866A1 (en) | 2018-01-31 |
| KR20170131506A (ko) | 2017-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011392A (es) | P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion. | |
| CU24419B1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
| CU20170087A7 (es) | Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| EA201691799A1 (ru) | Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| MX2016013052A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| EA201890124A1 (ru) | Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| UA113643C2 (xx) | N-цикліламіди як нематоциди | |
| CR20200177A (es) | Compuestos de biheteroarilo (divisional 2015-0589) | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| MX2017002206A (es) | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos. | |
| PE20170300A1 (es) | Procesos para preparar un inhibidor de jak 1 y nuevas formas de este | |
| EA201492223A1 (ru) | Новые диазаспироциклоалканы и азаспироциклоалканы | |
| CL2017002813A1 (es) | Proceso para preparar 4-amino-piridazinas | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201891440A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| AR104342A1 (es) | Compuesto heterocíclico | |
| MX2018003832A (es) | Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo. | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| MX2016013162A (es) | Proceso para la fabricacion de medicamentos. | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 |